Ipsen and exicure enter into exclusive collaboration targeting rare neurodegenerative disorders

Paris & chicago & cambridge, mass.--(business wire)--regulatory news: disclaimer: intended for international media and investor audiences only ipsen (euronext: ipn; adr: ipsey) and exicure inc. (nasdaq: xcur) have signed an exclusive collaboration agreement to research, develop, and commercialize novel spherical nucleic acids (snas) as potential investigational treatments for huntington's disease and angelman syndrome. oligonucleotides are synthetic structures of nucleic acids that can be used
XCUR Ratings Summary
XCUR Quant Ranking